Nonprofit group helps doctors and startups bring new cardiovascular tech to market

 

Nabil Dib, MD, founder of the nonprofit International Society for Cardiovascular Translational Research (ISCTR), spoke to Cardiovascular Business about the different resources ISCTR has developed to help doctors navigate the shift from conducting research to developing clinical applications.

"If you want to develop a drug or a device, it will take on average 20 years and take between $1.6 billion and $2 billion. What we put together are courses and eBooks on innovation that standardize medical product development, from identifying a patient need, developing intellectual property, understanding engineering language so you can communicate effectively, choosing the right animal models, understanding the clinical research and how to design trials with an important clinical endpoint. And all these things will meet the requirements for regulatory pathways," Dib, who is also the director of clinical and translational research with Dignity Health, explained.

The mission of ISCTR is to help move things more rapidly for new technology development by sharing the knowledge of those with previous experience. It provides a collaboration and guidance among academia, industry, regulatory agencies, reimbursement agencies, practice guidelines and patients to expedite scientific discoveries into commercialized products.

Dib is president of the organization, and its board of directors includes top innovators in cardiology such as Anthony DeMaria, Mitchell W. Krucoff, Spencer B. King, Martin B. Leon, Ron Waksman, Bram Zuckerman, Antonio Colombo, Jeroen Bax, David R. Holmes, Kenneth Stein, Chuck Simonton, Daniel Burkhoff, Todd J. Brinton, and others.

Dave Fornell is a digital editor with Cardiovascular Business and Radiology Business magazines. He has been covering healthcare for more than 16 years.

Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: [email protected]

Around the web

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.

The imaging manufacturer expects to spend between $227 million and $340 million on tariff mitigation efforts, leaders said Wednesday.